As on Wednesday, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) got off with the flyer as it spiked 11.67% to $14.07, before settling in for the price of $12.6 at the close. Taking a more long-term approach, AMLX posted a 52-week range of $2.60-$16.96.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -78.71%. Meanwhile, its Annual Earning per share during the time was -78.71%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 65.04%. This publicly-traded company’s shares outstanding now amounts to $109.77 million, simultaneously with a float of $91.70 million. The organization now has a market capitalization sitting at $1.55 billion.
Amylyx Pharmaceuticals Inc (AMLX) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Drug Manufacturers – Specialty & Generic industry. Amylyx Pharmaceuticals Inc’s current insider ownership accounts for 16.50%, in contrast to 94.84% institutional ownership. According to the most recent insider trade that took place on Jan 06 ’26, this organization’s Chief Financial Officer sold 3,326 shares at the rate of 11.11, making the entire transaction reach 36,954 in total value, affecting insider ownership by 177,104. Preceding that transaction, on Jan 06 ’26, Company’s Co-Chief Executive Officer sold 7,715 for 11.09, making the whole transaction’s value amount to 85,596. This particular insider is now the holder of 3,317,632 in total.
Amylyx Pharmaceuticals Inc (AMLX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
Amylyx Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 65.04% and is forecasted to reach -1.15 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 33.77% through the next 5 years, which can be compared against the -78.71% growth it accomplished over the previous five years trading on the market.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Let’s observe the current performance indicators for Amylyx Pharmaceuticals Inc (AMLX). It’s Quick Ratio in the last reported quarter now stands at 13.70.
In the same vein, AMLX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.80, a figure that is expected to reach -0.35 in the next quarter, and analysts are predicting that it will be -1.15 at the market close of one year from today.
